Lantern Pharma Inc. financial data

Symbol
LTRN on Nasdaq
Location
1920 Mckinney Avenue, 7 Th Floor, Dallas, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 437 % -56.2%
Debt-to-equity 29.4 % +162%
Return On Equity -126 % -121%
Return On Assets -97.4 % -90.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.2M shares +3.71%
Common Stock, Shares, Outstanding 11M shares +2.37%
Entity Public Float 44.3M USD -15.8%
Common Stock, Value, Issued 1.1K USD +2.41%
Weighted Average Number of Shares Outstanding, Basic 10.8M shares +0.65%
Weighted Average Number of Shares Outstanding, Diluted 10.8M shares +0.65%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13M USD -15.5%
General and Administrative Expense 6.63M USD +15%
Operating Income (Loss) -19.7M USD +7.2%
Net Income (Loss) Attributable to Parent -18.9M USD +0.9%
Earnings Per Share, Basic -1 USD/shares +1.13%
Earnings Per Share, Diluted -1 USD/shares +1.13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.39M USD +3.54%
Marketable Securities, Current 3.97M USD -80.1%
Assets, Current 13.5M USD -55%
Property, Plant and Equipment, Net 36K USD -26.5%
Operating Lease, Right-of-Use Asset 93.1K USD -67.5%
Other Assets, Noncurrent 36.7K USD 0%
Assets 13.6M USD -55%
Liabilities, Current 4.04M USD +12.2%
Operating Lease, Liability, Noncurrent 13.5K USD -75.3%
Liabilities 4.04M USD +9.34%
Accumulated Other Comprehensive Income (Loss), Net of Tax 40.3K USD
Retained Earnings (Accumulated Deficit) -89.1M USD -27%
Stockholders' Equity Attributable to Parent 9.59M USD -64%
Liabilities and Equity 13.6M USD -55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.38M USD -42.6%
Net Cash Provided by (Used in) Financing Activities 54.7K USD
Net Cash Provided by (Used in) Investing Activities 3.24M USD
Common Stock, Shares Authorized 25M shares 0%
Common Stock, Shares, Issued 11M shares +2.37%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.13M USD +68.3%
Deferred Tax Assets, Valuation Allowance 17.8M USD +41.7%
Deferred Tax Assets, Gross 17.8M USD +41.7%
Operating Lease, Liability 94K USD -67.7%
Payments to Acquire Property, Plant, and Equipment 1.16K USD -47.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -18.9M USD +0.65%
Lessee, Operating Lease, Liability, to be Paid 97.7K USD -68.9%
Operating Lease, Liability, Current 94K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54.7K USD -12.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 54.7K USD -73.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.72K USD -83.8%
Deferred Tax Assets, Operating Loss Carryforwards 9.35M USD +26.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 54K USD +20%
Additional Paid in Capital 98.6M USD +1.91%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4.06K USD +18.8%
Deferred Tax Assets, Net of Valuation Allowance 6.13K USD +59.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%